Skip to main content
Top
Published in: Drugs & Aging 12/2018

01-12-2018 | Review Article

Evidence-Based Management of Diabetes in Older Adults

Author: Arshag D. Mooradian

Published in: Drugs & Aging | Issue 12/2018

Login to get access

Abstract

The number of older adults with diabetes is rapidly increasing worldwide. A variety of factors contribute to the age-related increase in the incidence of diabetes. The lack of empiric evidence in the field has limited the management guidelines to mostly expert opinion. Given uncertainty over the rate at which to lower blood glucose levels and the optimal method of doing so, the goals of diabetes control in older people must be individualized. If the patient requires insulin therapy, the newer insulins, with their improved pharmacodynamic consistency and reduced risk of hypoglycemia, should be preferred. Several oral agents are preferable for people with sufficient endogenous insulin because they do not cause hypoglycemia when used as monotherapy. Some of these oral agents have been found to have cardioprotective effects. Older people with diabetes also require management of the other risk factors for cardiovascular disease, with antihypertensive drugs, cholesterol-lowering agents and low-dose aspirin. However, the precise targets for blood pressure control and low-density lipoprotein (LDL) cholesterol levels continue to evolve as more data become available. Diabetes care in older adults should focus on enhancing the individual’s quality of life rather than trying to normalize blood glucose levels or reach predetermined blood pressure and LDL cholesterol targets.
Literature
2.
go back to reference Paolisso G. Pathophysiology of diabetes in elderly people. Acta Biomed. 2010;81(Suppl 1):47–53.PubMed Paolisso G. Pathophysiology of diabetes in elderly people. Acta Biomed. 2010;81(Suppl 1):47–53.PubMed
3.
go back to reference Mooradian AD. Mechanisms of age-related endocrine alterations. Part II. Drugs Aging. 1993;3:131–46.PubMed Mooradian AD. Mechanisms of age-related endocrine alterations. Part II. Drugs Aging. 1993;3:131–46.PubMed
4.
go back to reference Giddings SJ, Carnaghi LR, Mooradian AD. Age-related changes in pancreatic islet cell gene expression. Metabolism. 1995;44:320–4.PubMed Giddings SJ, Carnaghi LR, Mooradian AD. Age-related changes in pancreatic islet cell gene expression. Metabolism. 1995;44:320–4.PubMed
5.
go back to reference Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus, California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. J Am Geriatr Soc. 2003;51(5 supplement):S265–80.PubMed Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus, California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. J Am Geriatr Soc. 2003;51(5 supplement):S265–80.PubMed
6.
go back to reference Olson DE, Norris SL. Diabetes in older adults. Overview of AGS guidelines for the treatment of diabetes mellitus in geriatric populations. Geriatrics. 2004;59:18–24.PubMed Olson DE, Norris SL. Diabetes in older adults. Overview of AGS guidelines for the treatment of diabetes mellitus in geriatric populations. Geriatrics. 2004;59:18–24.PubMed
7.
go back to reference Sinclair AJ, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Mañas L, European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab. 2011;37(Suppl 3):S27–38.PubMed Sinclair AJ, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Mañas L, European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab. 2011;37(Suppl 3):S27–38.PubMed
8.
go back to reference Durso SC. Using clinical guidelines for older adult patients with diabetes mellitus and complex health status. JAMA. 2006;295:1935–40.PubMed Durso SC. Using clinical guidelines for older adult patients with diabetes mellitus and complex health status. JAMA. 2006;295:1935–40.PubMed
9.
go back to reference Maty SC, Fried LP, Volpato S, et al. Patterns of disability related to diabetes mellitus in older women. J Gerontol A Biol Sci Med Sci. 2004;59:148–53.PubMed Maty SC, Fried LP, Volpato S, et al. Patterns of disability related to diabetes mellitus in older women. J Gerontol A Biol Sci Med Sci. 2004;59:148–53.PubMed
10.
go back to reference Wray LA, Ofstedal MB, Langa KM, et al. The effect of diabetes on disability in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2005;60:1206–11.PubMed Wray LA, Ofstedal MB, Langa KM, et al. The effect of diabetes on disability in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2005;60:1206–11.PubMed
11.
go back to reference Volpato S, Leveille SG, Blaum C, Fried LP, Guralnik JM. Risk factors for falls in older disabled women with diabetes: the women’s health and aging study. J Gerontol A Biol Sci Med Sci. 2005;60:1539–45.PubMedPubMedCentral Volpato S, Leveille SG, Blaum C, Fried LP, Guralnik JM. Risk factors for falls in older disabled women with diabetes: the women’s health and aging study. J Gerontol A Biol Sci Med Sci. 2005;60:1539–45.PubMedPubMedCentral
12.
go back to reference Mooradian AD. Psychosocial aspects of diabetes in the elderly. Diabetes Spectr. 1989;2:170–2. Mooradian AD. Psychosocial aspects of diabetes in the elderly. Diabetes Spectr. 1989;2:170–2.
13.
go back to reference Feldman SM, Rosen R, De Stasio J. Status of diabetes management in the nursing home setting in 2008: a retrospective chart review and epidemiology study of diabetic nursing home residents and nursing home initiatives in diabetes management. J Am Med Dir Assoc. 2009;10:354–60.PubMed Feldman SM, Rosen R, De Stasio J. Status of diabetes management in the nursing home setting in 2008: a retrospective chart review and epidemiology study of diabetic nursing home residents and nursing home initiatives in diabetes management. J Am Med Dir Assoc. 2009;10:354–60.PubMed
14.
go back to reference Mooradian AD. Diabetes as a model of premature aging. In: Cohn M, editor. Handbook of models for human aging. Burlington, MA: Elsevier Academic Press; 2006. p. 687–95. Mooradian AD. Diabetes as a model of premature aging. In: Cohn M, editor. Handbook of models for human aging. Burlington, MA: Elsevier Academic Press; 2006. p. 687–95.
15.
go back to reference Mooradian AD. Tissue specificity of premature aging in diabetes mellitus: the role of cellular replicative capacity. J Am Geriatr Soc. 1988;36:831–9.PubMed Mooradian AD. Tissue specificity of premature aging in diabetes mellitus: the role of cellular replicative capacity. J Am Geriatr Soc. 1988;36:831–9.PubMed
16.
go back to reference Morisaki N, Watanabe S, Kobayashi J, Kanzaki T, Takahashi K, Yokote K, Tezuka M, Tashiro J, Inadera H, Saito Y, et al. Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J Am Geriatr Soc. 1994;42:142–5.PubMed Morisaki N, Watanabe S, Kobayashi J, Kanzaki T, Takahashi K, Yokote K, Tezuka M, Tashiro J, Inadera H, Saito Y, et al. Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J Am Geriatr Soc. 1994;42:142–5.PubMed
17.
go back to reference Barnett KN, McMurdo ME, Ogston SA, Morris AD, Evans JM. Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review. Age Ageing. 2006;35:463–8.PubMed Barnett KN, McMurdo ME, Ogston SA, Morris AD, Evans JM. Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review. Age Ageing. 2006;35:463–8.PubMed
18.
go back to reference Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720–32.PubMed Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720–32.PubMed
19.
go back to reference Huo L, Magliano DJ, Rancière F, Harding JL, Nanayakkara N, Shaw JE, Carstensen B. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997–2011. Diabetologia. 2018;61:1055–63.PubMed Huo L, Magliano DJ, Rancière F, Harding JL, Nanayakkara N, Shaw JE, Carstensen B. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997–2011. Diabetologia. 2018;61:1055–63.PubMed
20.
go back to reference Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, Marre M, Patel A, Poulter N, Williams B, Chalmers J, ADVANCE Collaborative group. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57:2465–74.PubMed Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, Marre M, Patel A, Poulter N, Williams B, Chalmers J, ADVANCE Collaborative group. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57:2465–74.PubMed
21.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMed Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMed
22.
go back to reference Leske MC, Sperduto RD. The epidemiology of senile cataracts: a review. Am J Epidemiol. 1983;118:152–65.PubMed Leske MC, Sperduto RD. The epidemiology of senile cataracts: a review. Am J Epidemiol. 1983;118:152–65.PubMed
23.
go back to reference Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol. 1983;118:166–91.PubMed Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol. 1983;118:166–91.PubMed
24.
go back to reference Morley JE, Mooradian AD, Rosenthal MH, Kaiser FE. Diabetes mellitus in the elderly: is it different? Am J Med. 1987;83:533–44.PubMed Morley JE, Mooradian AD, Rosenthal MH, Kaiser FE. Diabetes mellitus in the elderly: is it different? Am J Med. 1987;83:533–44.PubMed
25.
go back to reference Evans SL, Nixon BP, Lee I, Yee D, Mooradian AD. The prevalence and nature of podiatric problems in elderly diabetic patients. J Am Geriatr Soc. 1991;39:241–5.PubMed Evans SL, Nixon BP, Lee I, Yee D, Mooradian AD. The prevalence and nature of podiatric problems in elderly diabetic patients. J Am Geriatr Soc. 1991;39:241–5.PubMed
26.
go back to reference Mooradian AD, Korenman SG. Management of the cardinal features of andropause. Am J Ther. 2006;13:145–60.PubMed Mooradian AD, Korenman SG. Management of the cardinal features of andropause. Am J Ther. 2006;13:145–60.PubMed
27.
go back to reference Wachtel TJ. The diabetic-hyperosmolar state. Clin Geriatr Med. 1990;6:797–806.PubMed Wachtel TJ. The diabetic-hyperosmolar state. Clin Geriatr Med. 1990;6:797–806.PubMed
28.
go back to reference Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, Shorr RI, Vinik AI, Odden MC, Park SW, Faulkner KA, Harris TB, Health, Aging, and Body Composition Study. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31:391–6.PubMed Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, Shorr RI, Vinik AI, Odden MC, Park SW, Faulkner KA, Harris TB, Health, Aging, and Body Composition Study. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31:391–6.PubMed
29.
go back to reference Blaum CS, Ofstedal MB, Langa KM, et al. Functional status and health outcomes in older Americans with diabetes mellitus. J Am Geriatr Soc. 2003;51:745–53.PubMed Blaum CS, Ofstedal MB, Langa KM, et al. Functional status and health outcomes in older Americans with diabetes mellitus. J Am Geriatr Soc. 2003;51:745–53.PubMed
30.
go back to reference Blaum CS, Xue QL, Tian J, Semba RD, Fried LP, Walston J. Is hyperglycemia associated with frailty status in older women? J Am Geriatr Soc. 2009;57:840–7.PubMedPubMedCentral Blaum CS, Xue QL, Tian J, Semba RD, Fried LP, Walston J. Is hyperglycemia associated with frailty status in older women? J Am Geriatr Soc. 2009;57:840–7.PubMedPubMedCentral
31.
go back to reference Mooradian AD, Perryman K, Fitten J, Kavonian G, Morley JE. Cortical function in elderly non-insulin dependent diabetic patients: behavioral and electrophysiological studies. Arch Int Med. 1988;148:2369–72. Mooradian AD, Perryman K, Fitten J, Kavonian G, Morley JE. Cortical function in elderly non-insulin dependent diabetic patients: behavioral and electrophysiological studies. Arch Int Med. 1988;148:2369–72.
32.
go back to reference Mooradian AD. Diabetic complications of the central nervous system. Endocr Rev. 1988;9:346–56.PubMed Mooradian AD. Diabetic complications of the central nervous system. Endocr Rev. 1988;9:346–56.PubMed
33.
go back to reference Mooradian AD, Siverly FD. Qualitative differences in the visual retention test performance of older non-insulin dependent diabetic patients. Age. 1993;16:67–9. Mooradian AD, Siverly FD. Qualitative differences in the visual retention test performance of older non-insulin dependent diabetic patients. Age. 1993;16:67–9.
34.
go back to reference Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.PubMed Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.PubMed
35.
go back to reference Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
36.
go back to reference American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55–64. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55–64.
37.
go back to reference Chung SC, Hlatky MA, Faxon D, Ramanathan K, Adler D, Mooradian A, Rihal C, Stone RA, Bromberger JT, Kelsey SF, Brooks MM, BARI 2D Study Group. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). J Am Coll Cardiol. 2011;58:810–9.PubMedPubMedCentral Chung SC, Hlatky MA, Faxon D, Ramanathan K, Adler D, Mooradian A, Rihal C, Stone RA, Bromberger JT, Kelsey SF, Brooks MM, BARI 2D Study Group. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). J Am Coll Cardiol. 2011;58:810–9.PubMedPubMedCentral
38.
go back to reference Damluji AA, Cohen ER, Moscucci M, Myerburg RJ, Cohen MG, Brooks MM, Rich MW, Forman DE. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial. Int J Cardiol. 2017;241:35–40.PubMed Damluji AA, Cohen ER, Moscucci M, Myerburg RJ, Cohen MG, Brooks MM, Rich MW, Forman DE. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial. Int J Cardiol. 2017;241:35–40.PubMed
39.
go back to reference Mooradian AD, Chehade JM. Diabetes mellitus in older adults. Am J Ther. 2012;19:145–59.PubMed Mooradian AD, Chehade JM. Diabetes mellitus in older adults. Am J Ther. 2012;19:145–59.PubMed
40.
go back to reference Holvey SM. Psychosocial aspects in the care of elderly diabetic patients. Am J Med. 1986;8(suppl 5A):61–3. Holvey SM. Psychosocial aspects in the care of elderly diabetic patients. Am J Med. 1986;8(suppl 5A):61–3.
41.
go back to reference Mooradian AD. Behavioral effects if noninsulin-dependent diabetes mellitus in the elderly. Neurobiol Aging. 1994;15:565–7.PubMed Mooradian AD. Behavioral effects if noninsulin-dependent diabetes mellitus in the elderly. Neurobiol Aging. 1994;15:565–7.PubMed
42.
go back to reference Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T. The pathways study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61:1042–9.PubMed Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T. The pathways study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61:1042–9.PubMed
43.
go back to reference American Diabetes Association. 2. Diagnosis and classification of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–27. American Diabetes Association. 2. Diagnosis and classification of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–27.
44.
go back to reference Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, Narayan KM, Koch DD, Phillips LS. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152:770–7.PubMed Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, Narayan KM, Koch DD, Phillips LS. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152:770–7.PubMed
45.
go back to reference Mooradian AD, Morin A, Clip L, Haspel H. Glucose transport is reduced in the blood–brain barrier of aged rats. Brain Res. 1991;551:145–9.PubMed Mooradian AD, Morin A, Clip L, Haspel H. Glucose transport is reduced in the blood–brain barrier of aged rats. Brain Res. 1991;551:145–9.PubMed
46.
go back to reference Mooradian AD, Scarpace PJ. β-Adrenergic receptor activity of cerebral microvessels is reduced in aged rats. Neurochem Res. 1991;16:447–51.PubMed Mooradian AD, Scarpace PJ. β-Adrenergic receptor activity of cerebral microvessels is reduced in aged rats. Neurochem Res. 1991;16:447–51.PubMed
47.
go back to reference Mooradian AD. Central nervous system complications of diabetes mellitus. A perspective from the blood–brain barrier. Brain Res Rev. 1997;23:210–8.PubMed Mooradian AD. Central nervous system complications of diabetes mellitus. A perspective from the blood–brain barrier. Brain Res Rev. 1997;23:210–8.PubMed
48.
go back to reference Mooradian AD. Pathophysiology of central nervous system disorders in diabetes. Clin Neurosci. 1997;4:322–6.PubMed Mooradian AD. Pathophysiology of central nervous system disorders in diabetes. Clin Neurosci. 1997;4:322–6.PubMed
49.
go back to reference Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269–76.PubMed Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269–76.PubMed
50.
go back to reference Niefeld MR, Braunstein JB, Wu AW, Saudek CD, Weller WE, Anderson GF. Hospitalization among elderly medicare beneficiaries with type 2 diabetes. Diabetes Care. 2003;26:1344–9.PubMed Niefeld MR, Braunstein JB, Wu AW, Saudek CD, Weller WE, Anderson GF. Hospitalization among elderly medicare beneficiaries with type 2 diabetes. Diabetes Care. 2003;26:1344–9.PubMed
51.
go back to reference Druss BG, Marcus SC, Olfson M, Tanielian T, Elinson L, Pincus HA. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood). 2001;20:233–41. Druss BG, Marcus SC, Olfson M, Tanielian T, Elinson L, Pincus HA. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood). 2001;20:233–41.
52.
go back to reference Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29:725–31.PubMed Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29:725–31.PubMed
53.
go back to reference Reed RL, Mooradian AD. Nutritional status and dietary management of elderly diabetic patients. Clin Geriatr Med. 1990;6:883–902.PubMed Reed RL, Mooradian AD. Nutritional status and dietary management of elderly diabetic patients. Clin Geriatr Med. 1990;6:883–902.PubMed
54.
go back to reference Mooradian AD, Osterweil D, Petrasek D, Morley JE. Diabetes mellitus in the elderly nursing home patients: a survey of clinical characteristics and management. J Am Geriatr Soc. 1988;36:391–6.PubMed Mooradian AD, Osterweil D, Petrasek D, Morley JE. Diabetes mellitus in the elderly nursing home patients: a survey of clinical characteristics and management. J Am Geriatr Soc. 1988;36:391–6.PubMed
55.
go back to reference Mooradian AD, Kalis J, Nugent CA. The nutritional status of ambulatory elderly type II diabetic patients. Age. 1990;13:87–9. Mooradian AD, Kalis J, Nugent CA. The nutritional status of ambulatory elderly type II diabetic patients. Age. 1990;13:87–9.
56.
go back to reference Thurman JE. Mooradian AD Vitamin supplementation therapy in the elderly. Drugs Aging. 1997;11:433–49.PubMed Thurman JE. Mooradian AD Vitamin supplementation therapy in the elderly. Drugs Aging. 1997;11:433–49.PubMed
57.
go back to reference Binder EF, Yarasheski KE, Steger-May K, Sinacore DR, Brown M, Schechtman KB, Holloszy JO. Effects of progressive resistance training on body composition in frail older adults: results of a randomized, controlled trial. J Gerontol A Biol Sci Med Sci. 2005;60:1425–31.PubMed Binder EF, Yarasheski KE, Steger-May K, Sinacore DR, Brown M, Schechtman KB, Holloszy JO. Effects of progressive resistance training on body composition in frail older adults: results of a randomized, controlled trial. J Gerontol A Biol Sci Med Sci. 2005;60:1425–31.PubMed
58.
go back to reference Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med. 1994;330:1769–75.PubMed Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med. 1994;330:1769–75.PubMed
59.
go back to reference Mooradian AD. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs. 1996;6:931–41. Mooradian AD. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs. 1996;6:931–41.
60.
go back to reference Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000;60:95–113.PubMed Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000;60:95–113.PubMed
61.
go back to reference Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. Biomed Pharmacother. 2003;57:231–9.PubMed Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. Biomed Pharmacother. 2003;57:231–9.PubMed
62.
go back to reference Chehade J, Mooradian AD. Drug therapy: current and emerging agents for hyperglycemia. In: Sinclair AJ, editor. Diabetes in old age. 3rd ed. Hoboken: Wiley; 2009. p. 245–64. Chehade J, Mooradian AD. Drug therapy: current and emerging agents for hyperglycemia. In: Sinclair AJ, editor. Diabetes in old age. 3rd ed. Hoboken: Wiley; 2009. p. 245–64.
63.
go back to reference Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMed Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMed
64.
go back to reference ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.
65.
go back to reference Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723–32.PubMedPubMedCentral Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723–32.PubMedPubMedCentral
66.
go back to reference Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes. Drugs. 2005;65:325–40.PubMed Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes. Drugs. 2005;65:325–40.PubMed
67.
go back to reference Mooradian AD, Bernbaum M, Albert SG. A narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145:125–34.PubMed Mooradian AD, Bernbaum M, Albert SG. A narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145:125–34.PubMed
68.
go back to reference Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc. 2007;55:182–8.PubMed Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc. 2007;55:182–8.PubMed
69.
go back to reference Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568–73.PubMed Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568–73.PubMed
70.
go back to reference Schwartz TB, Meinert CL. The UGDP controversy: 34 years of contentious ambiguity laid to rest. Perspect Biol Med. 2004;47:564–74.PubMed Schwartz TB, Meinert CL. The UGDP controversy: 34 years of contentious ambiguity laid to rest. Perspect Biol Med. 2004;47:564–74.PubMed
71.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
72.
go back to reference Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicenter trial. Lancet Diabetes Endocrinol. 2017;5:887–97.PubMed Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicenter trial. Lancet Diabetes Endocrinol. 2017;5:887–97.PubMed
73.
go back to reference Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157:1681–6.PubMed Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157:1681–6.PubMed
74.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.
75.
go back to reference Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet Lond Engl. 2009;373:2125–35. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet Lond Engl. 2009;373:2125–35.
76.
go back to reference Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–31.PubMedPubMedCentral Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–31.PubMedPubMedCentral
77.
go back to reference Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89.PubMed Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89.PubMed
78.
go back to reference Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94.PubMed Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94.PubMed
79.
go back to reference Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.PubMed Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.PubMed
80.
go back to reference Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877–86.PubMed Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877–86.PubMed
81.
go back to reference Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998;83:1515–22.PubMed Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998;83:1515–22.PubMed
82.
go back to reference Deleon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 (GLP-1) response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101–6.PubMed Deleon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 (GLP-1) response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101–6.PubMed
83.
go back to reference Mooradian AD, Albert SG, Wittry S, Chehade J, Kim J, Bellrichard B. Dose-response profile of acarbose in older subjects with Type 2 diabetes. Am J Med Sci. 2000;319:334–7.PubMed Mooradian AD, Albert SG, Wittry S, Chehade J, Kim J, Bellrichard B. Dose-response profile of acarbose in older subjects with Type 2 diabetes. Am J Med Sci. 2000;319:334–7.PubMed
84.
go back to reference Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–88. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–88.
85.
go back to reference Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–42.PubMed Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–42.PubMed
86.
go back to reference White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.PubMed White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.PubMed
87.
go back to reference Umpierrez GE, Cardona S, Chachkhiani D, et al. A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: Linagliptin-LTC Trial. J Am Med Dir Assoc. 2018;19:399–404.PubMed Umpierrez GE, Cardona S, Chachkhiani D, et al. A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: Linagliptin-LTC Trial. J Am Med Dir Assoc. 2018;19:399–404.PubMed
88.
go back to reference Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.PubMedPubMedCentral Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.PubMedPubMedCentral
89.
go back to reference Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.PubMed Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.PubMed
90.
go back to reference Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.PubMed Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.PubMed
91.
go back to reference Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39.PubMed Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39.PubMed
92.
go back to reference Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
93.
go back to reference Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
94.
go back to reference Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71:85–94.PubMed Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71:85–94.PubMed
95.
go back to reference Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.PubMed Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.PubMed
96.
go back to reference ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.
97.
go back to reference Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85.PubMed Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85.PubMed
98.
go back to reference Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.PubMed Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.PubMed
99.
go back to reference Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Lond Engl. 2010;376:1670–81. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Lond Engl. 2010;376:1670–81.
100.
go back to reference Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45.PubMed Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45.PubMed
101.
go back to reference HPS Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet Lond Engl. 2002;360:7–22. HPS Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet Lond Engl. 2002;360:7–22.
102.
go back to reference Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.PubMed Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.PubMed
103.
go back to reference Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.PubMed Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.PubMed
105.
go back to reference Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70:1785–822.PubMed Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70:1785–822.PubMed
106.
go back to reference Mooradian AD. Dyslipidemia of type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150–9.PubMed Mooradian AD. Dyslipidemia of type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150–9.PubMed
107.
go back to reference Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood pressure control (SPRINT). N Engl J Med. 2015;373:2103–16.PubMed Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood pressure control (SPRINT). N Engl J Med. 2015;373:2103–16.PubMed
108.
go back to reference Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. The ACCORD study group. N Engl J Med. 2010;362:1575–85.PubMed Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. The ACCORD study group. N Engl J Med. 2010;362:1575–85.PubMed
109.
go back to reference Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure lowering treatment on outcome incidence in hypertension: 10—should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922–44.PubMed Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure lowering treatment on outcome incidence in hypertension: 10—should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922–44.PubMed
110.
go back to reference Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects metaanalyses of randomized trials. Circulation. 2011;123:2799–810.PubMed Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects metaanalyses of randomized trials. Circulation. 2011;123:2799–810.PubMed
111.
go back to reference Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet Lond Engl. 2016;387:957–67. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet Lond Engl. 2016;387:957–67.
112.
go back to reference Whelton PK, Carey RM, Aronow WSD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. JACC. 2018;71:e127–248.PubMed Whelton PK, Carey RM, Aronow WSD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. JACC. 2018;71:e127–248.PubMed
113.
go back to reference James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.PubMed James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.PubMed
114.
go back to reference Aronow WS, Frishman WH. Contemporary drug treatment of hypertension: focus on recent guidelines. Drugs. 2018;78:567–76.PubMed Aronow WS, Frishman WH. Contemporary drug treatment of hypertension: focus on recent guidelines. Drugs. 2018;78:567–76.PubMed
115.
go back to reference Chrysant SG. Aggressive systolic blood pressure control in older subjects: benefits and risks. Postgrad Med. 2018;130:159–65.PubMed Chrysant SG. Aggressive systolic blood pressure control in older subjects: benefits and risks. Postgrad Med. 2018;130:159–65.PubMed
116.
go back to reference Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016;134:1579–94.PubMed Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016;134:1579–94.PubMed
118.
go back to reference American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S86–104. American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S86–104.
119.
go back to reference Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. An update of the 2011 ACC/AHA/SCAI PCI guideline, 2011 ACC/AHA CABG guideline, 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS SIHD guideline, 2013 ACC/AHA STEMI guideline, 2014 ACC/AHA NSTE-ACS guideline, and 2014 ACC/AHA Perioperative guideline. J Am Coll Cardiol. 2016;68:1082–115.PubMed Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. An update of the 2011 ACC/AHA/SCAI PCI guideline, 2011 ACC/AHA CABG guideline, 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS SIHD guideline, 2013 ACC/AHA STEMI guideline, 2014 ACC/AHA NSTE-ACS guideline, and 2014 ACC/AHA Perioperative guideline. J Am Coll Cardiol. 2016;68:1082–115.PubMed
120.
go back to reference Bernbaum M, Albert SG, McGinnis J, Brusca S, Mooradian AD. The reliability of self blood glucose monitoring in elderly diabetic patients. J Am Geriatr Soc. 1994;42:779–81.PubMed Bernbaum M, Albert SG, McGinnis J, Brusca S, Mooradian AD. The reliability of self blood glucose monitoring in elderly diabetic patients. J Am Geriatr Soc. 1994;42:779–81.PubMed
121.
go back to reference Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;1:005060. Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;1:005060.
122.
go back to reference Mattishent K, Loke YK. Detection of asymptomatic drug-induced hypoglycemia using continuous glucose monitoring in older people—systematic review. J Diabetes Complicat. 2018;32:805–12.PubMed Mattishent K, Loke YK. Detection of asymptomatic drug-induced hypoglycemia using continuous glucose monitoring in older people—systematic review. J Diabetes Complicat. 2018;32:805–12.PubMed
123.
go back to reference Reed RL, Mooradian AD. Management of diabetes mellitus in the nursing home. Ann Long Term Care. 1998;6:100–7. Reed RL, Mooradian AD. Management of diabetes mellitus in the nursing home. Ann Long Term Care. 1998;6:100–7.
124.
go back to reference Saxon DR, Rasouli N, Eckell RH. Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: established and emerging agents. Drugs. 2018;78:203–14.PubMed Saxon DR, Rasouli N, Eckell RH. Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: established and emerging agents. Drugs. 2018;78:203–14.PubMed
125.
go back to reference Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12:716–21.PubMed Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12:716–21.PubMed
126.
go back to reference Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother. 2010;44:904–9.PubMed Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother. 2010;44:904–9.PubMed
127.
go back to reference Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349–54.PubMedPubMedCentral Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349–54.PubMedPubMedCentral
128.
go back to reference Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ. Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care. 2018;41:1809–16.PubMed Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ. Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care. 2018;41:1809–16.PubMed
Metadata
Title
Evidence-Based Management of Diabetes in Older Adults
Author
Arshag D. Mooradian
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 12/2018
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-018-0598-3

Other articles of this Issue 12/2018

Drugs & Aging 12/2018 Go to the issue

Acknowledgement to Referees

Acknowledgment to Referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.